Immunwork, Inc. was founded in 2014. We focus on the research, development and commercialization of a series of new drugs, which are created based on our proprietary “T-ETM pharmaceuticals” technology platform, for treating multiple types of cancer, diabetes, non-alcoholic steatohepatitis (NASH), obesity, pathological blood clots, osteoporosis, and other selected severe clinical conditions.
The drug-design platform can be employed for constructing antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), ultra-long-acting peptide drugs, and other pharmaceutical configurations. Five drug candidates have been identified and are planned to enter preclinical development, including TE-8214 and TE-1146 for treating oncology, TE-8104 for treating diabetes, and TE-6168 for treating pathological clots.
|2014||Immunwork, Inc. was founded in October 2014.|
|2019||After a corporate reorganization in November 2019, Immunwork is now a wholly owned subsidiary of T-E Pharma Holding, incorporated in Cayman Island.|
|2021||T-E Pharma Holding (TEPH) is to issue common shares for raising.|
|2021||TE-8105 is recognized by CDE as Index Case|